Hybrid solid–liquid optics improve light-sheet imaging of intact biological samples.

Plant genome editing is multiplexed with twin prime editing.

Folddisco enables protein structural motif search in million scale databases.

Interactions between the tumor microenvironment and antibody drugs are imaged with spatial proteomics.

A Cas13-based gene switch allows multiplexed RNA regulation in bacteria.

Selection increases the purity of blood stem cells bearing targeted homologous recombination.

Biotech is back. But continued investor caution, the rise of China and fast-moving AI are changing the sector’s contours.

Sub-zero technologies that reduce ice damage in organs could extend donor-graft shelf life — offering transplant centers more time to match recipients.

The significance of the first FDA-approved PROTAC lies not in proving that targeted protein degradation is superior to conventional therapies, but in proving that degrading proteins is possible as a therapeutic.

This Comment explores artificial intelligence-driven strategies to accelerate the clinical translation of multimodal wearable sensors. We outline key data-science challenges and highlight disease contexts in which these systems could support therapeutic interventions.

Building a living cell from scratch requires overcoming a bottleneck that has remained unresolved despite decades of progress: orchestrating the spatiotemporal integration of core functional modules. To tackle this barrier, the SynCell Asia Initiative outlines a strategy for developing core functional modules followed by their systems-level integration through the establishment of a centralized, artificial intelligence (AI)-driven biofoundry.

Faster drug discovery, optimized drug design, even programmable therapeutics: AI is impacting R&D. Data and development bottlenecks remain.